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Induction of Alternatively Activated Macrophages Enhances
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Infection
Carly Page,a Lindsay Goicochea,b Krystal Matthews,a Yong Zhang,c Peter Klover,d* Michael J. Holtzman,c,e Lothar Hennighausen,d
and Matthew Friemana
Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, Maryland, USAa; Department of Pathology, University of Maryland School
of Medicine, Baltimore, Maryland, USAb; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USAc; Laboratory of Genetics and
Physiology, National Institutes of Health, Bethesda, Maryland, USAd; and Department of Cell Biology, Washington University School of Medicine, St. Louis, Missouri, USAe
Infection with severe acute respiratory syndrome coronavirus (SARS-CoV) causes acute lung injury (ALI) that often leads to se-
vere lung disease. A mouse model of acute SARS-CoV infection has been helpful in understanding the host response to infection;
however, there are still unanswered questions concerning SARS-CoV pathogenesis. We have shown that STAT1 plays an impor-
tant role in the severity of SARS-CoV pathogenesis and that it is independent of the role of STAT1 in interferon signaling. Mice
lacking STAT1 have greater weight loss, severe lung pathology with pre-pulmonary-fibrosis-like lesions, and an altered immune
response following infection with SARS-CoV.We hypothesized that STAT1 plays a role in the polarization of the immune re-
sponse, specifically in macrophages, resulting in a worsened outcome. To test this, we created bone marrow chimeras and cell-
type-specific knockouts of STAT1 to identify which cell type(s) is critical to protection from severe lung disease after SARS-CoV
infection. Bone marrow chimera experiments demonstrated that hematopoietic cells are responsible for the pathogenesis in
STAT1/mice, and because of an induction of alternatively activated (AA) macrophages after infection, we hypothesized that
the AAmacrophages were critical for disease severity. Mice with STAT1 in either monocytes andmacrophages (LysM/STAT1) or
ciliated lung epithelial cells (FoxJ1/STAT1) deleted were created. Following infection, LysM/STAT1mice display severe lung pa-
thology, while FoxJ1/STAT1mice display normal lung pathology. We hypothesized that AAmacrophages were responsible for
this STAT1-dependent pathology and therefore created STAT1/STAT6/ double-knockout mice. STAT6 is essential for the de-
velopment of AAmacrophages. Infection of the double-knockout mice displayed a lack of lung disease and prefibrotic lesions,
suggesting that AAmacrophage productionmay be the cause of STAT1-dependent lung disease. We propose that the control of
AA macrophages by STAT1 is critical to regulating immune pathologies and for protection from long-term progression to
fibrotic lung disease in a mouse model of SARS-CoV infection.
Infection with a variety of respiratory viruses, including influ-enza virus H1N1 (25, 37, 50) and severe acute respiratory syn-
drome coronavirus (SARS-CoV) (9, 13, 18, 49), is known to cause
acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS), leading to high rates of severe morbidity and mortality
(1, 26). In the case of the 2002 SARS-CoV pandemic, there were
nearly 8,000 cases and 800 deaths worldwide, with many of these
deaths occurring due to development of ARDS in elderly patients
(28, 29, 32). It is hypothesized that ALI and ARDS develop from
both intrinsic viral infection and dysregulation of the host im-
mune response to infection, although the exact mechanism is not
fully understood.
In acute infections with SARS-CoV, lung damage rapidly pro-
gresses to diffuse alveolar damage (DAD), resulting clinically in
ARDS, which is considered to be the most severe form of ALI (13,
18, 28, 49). ARDS is known to develop from a variety of etiologies
that cause severe lung damage and presents a major challenge in
critical care medicine, with nearly 1 million deaths attributed to
ARDS each year (1). The predominant pathological feature of
SARS-CoV infection is diffuse alveolar damage, including hyaline
membrane formation, which together clinicallymanifest as ARDS
(9, 49). Even after resolution of SARS, DAD can still be observed
by a computed-tomography (CT) scan, and a high proportion of
these patients progress to develop pulmonary fibrosis (18).
The host response to viral infection is critical for proper reso-
lution of disease. When that response is altered by the pathogen,
the incorrect response can lead to significant tissue damage and
further disease. The innate immune response has been shown to
protect mice from SARS-CoV replication both in vitro and in vivo
(14, 15, 19, 27, 45, 46, 65, 72, 78). Specifically, infection of
STAT1/mice on the 129/Sv background with a human isolate
of SARS-CoV demonstrated that STAT1 (signal transducers and
activators of transcription 1) was necessary to control viral repli-
cation and spread (15, 79).
We have identified STAT1 as a key mediator controlling the
proper host response to SARS-CoV infection (15, 79). STAT1 is a
member of the signal transducers and activators of transcription
family of transcription factors and plays an important role in both
innate and adaptive immune function, as well as cell cycle regula-
tion (33, 35). STAT1’s function in cell cycle control makes it of
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interest in potentially contributing to pulmonary fibrosis devel-
opment following acute lung injury. In instances where epidermal
growth factor (EGF) signaling mediates cell cycle arrest rather
than growth, it has been shown that STAT1 is an important sig-
naling component that negatively regulates the EGF pathway (2,
47). It has also been demonstrated that STAT1/mice are prone
to the development of spontaneous tumors and aremore sensitive
to varying in vivo models of cancer, including esophageal cancer
and melanoma (71, 73). STAT1-deficient mice have also been
shown to be sensitive to radiation- and bleomycin-induced fibro-
sis, again illustrating STAT1’s role in control of the regulation of
cell cycle progression and proliferation (70).
The involvement of STAT1 in viral infections is associatedwith
its activity in the interferon signaling pathway and the innate im-
mune response (11, 40, 62). In the case of SARS-CoV infection, we
have shown that in 129/Sv mice, STAT1 is important in pathways
other than the interferon signaling pathway (15). In this model,
we found that SARS-CoV infection of mice lacking the alpha/beta
interferon receptor (IFNAR1), gamma interferon (IFN-) recep-
tor (IFNGR), or interferon lambda receptor (IL28Ra) and IFNAR/
IFNGR double mutants display no enhanced pathogenesis, while
STAT1/ mice are highly susceptible and display severe lung
disease and pathology (15). STAT1/mice in this genetic back-
ground have an inability to clear virus by 9 days postinfection and
proceed to develop a severe lung disease phenotype that closely
replicates the pathology seen in human patients during the SARS-
CoV outbreak (31, 49). This includes extensive mixed inflamma-
tory infiltrates, predominantly neutrophils, lymphocytes, and
macrophages, as well as pathological features of DAD. The data
suggest that a different STAT1-dependent pathway is critical for
host protection rather than STAT1’s role in IFN signaling. We
have shown that STAT1/ mice do show an altered immune
response to SARS-CoV infection, including an enhanced TH2
profile with a significant increase in genes related to the alterna-
tively activated subset of macrophages (15, 79).
Alternatively activated (AA) macrophages have been impli-
cated in models of lung disease, including asthma and pulmonary
fibrosis (16, 51, 75). In contrast to classical macrophages, which
become activated and differentiate in response to IFN-, AAmac-
rophages differentiate in response to interleukin 4 (IL-4) and
IL-13 (66). Induction of the AAmacrophage phenotype is depen-
dent upon IL-4R signaling, as well as the presence and activation
of STAT6 (7, 44, 67). Their functions also differ from that of
classically activated macrophages, as they are associated with
wound repair and healing rather than direct pathogen killing (16).
In mice, AA macrophages secrete the effector proteins YM1,
FIZZ1, and arginase 1 (16). These effector protein functions are
not yet fully understood, but their presence has been associated
with liver fibrosis (36, 51, 56), as well as allergic airway inflamma-
tion (3, 42). In this paper, we utilize a mouse model of SARS-CoV
infection to elucidate the role of STAT1 in ALI as it relates to the
induction of AAmacrophage subsets in the lung.We demonstrate
that the lack of STAT1 in the macrophage and monocyte lineage
can shift the immune response and produce significant lung in-
jury, as seen in total STAT1/mice.We also show that inhibition
of AA macrophage development in STAT1/mice, by knocking
out STAT6 in concert, protects them from severe lung disease and
prefibrotic lesions during SARS-CoV infection. These data dem-
onstrate the role of STAT1 in SARS-CoV pathogenesis, as well as
the role that macrophage subtypes play in repair of acute lung
injury and development of pulmonary-fibrosis-like diseases.
MATERIALS AND METHODS
Ethics statement. This study was carried out in strict accordance with the
recommendations in theGuide for the Care andUse of Laboratory Animals
of the National Institutes of Health. All mice in this study were treated
following IACUC guidelines, and procedures were approved by the Uni-
versity of Maryland School of Medicine IACUC. For infection, the mice
were pretreated with ketamine and xylazine as an anesthetic. Mice were
euthanized if their weight dropped below approved levels or if clinical
symptoms warranted it according to our IACUC protocol. Animal hous-
ing and care and experimental protocols were in accordance with all An-
imal Care and Use Committee guidelines.
Viruses and cells. SARS-CoV rMA15 was constructed as previously
described (57). All virus stocks were stored at 80°C until they were
ready to use. VeroE6 cells were purchased from ATCC (catalog num-
ber CRL-1586;Manassas, VA) and were used for growing rMA15 virus,
as well as plaque assays to determine the viral load in lung tissue. Cells
were grown in minimal essential medium (MEM) (Invitrogen, Carls-
bad, CA) with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA) and 1% penicillin/streptomycin (Gemini Bioprod-
ucts, West Sacramento, CA).
Mouse breeding. C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA). STAT1/mice were a gift from David
Levy (New York University [NYU]) and were bred and housed in the
animal facilities at the University of Maryland, Baltimore, MD (UMB).
For Cre/LoxP crosses, C57BL/6 LysM/Cre mice (catalog number
004781) were purchased from Jackson Laboratory (Bar Harbor, ME),
C57BL/6 FoxJ/Cremice were a gift fromMichael Holtzman (Washington
University in St. Louis), and C57BL/6 STAT1/LoxP mice were a gift from
LotharHennighausen (NIDDK,NIH) (24). C57BL/6 STAT1/LoxP female
mice were crossed with male LysM/Cre and FoxJ/Cre mice. Initial F1 pup
tails were genotyped for the presence of Cre with primers 5=-GCATTAC
CGGTCGATGCAACGAGTGATGAG-3= and 5=-GAGTGAACGAACCT
GGTCGAAATCAGTGCG-3= and for the STAT1/LoxP allelewith primers
5=-GCATGACATGATCAGCATTGC-3= and 5=-ACTGACGTCAACCAA
GCCTG-3=. F1-positive female pups were crossed back to STAT1/LoxP
males, and F2 pups were generated. These pups were screened for the
presence of Cre and 2 copies of the STAT1/LoxP allele. Dual-positive pups
were bred, and the lines were screened by immunohistochemistry (IHC)
and PCR for the presence of STAT1 in the affected tissue. The methods of
this screen are described below.
For STAT1/  STAT6/ double-knockout production, STAT6/
micewerepurchased fromJacksonLaboratory (BarHarbor,ME).STAT6/
micewere crossedwith STAT1/mice, andF1pupswere generated. The F1
pups were crossed, and F2 double-positive pups were produced. These pups
were screened for deletionof both genes byPCR, and selectedpupswere bred
for use in the infection experiments.
Histological analysis. Lung sections were fixed in 4% paraformalde-
hyde (PFA) in phosphate-buffered saline (PBS) for a minimum of 48 h,
after which they were sent to the Histology Core at the University of
Maryland, Baltimore, for paraffin embedding and sectioning. Five-mi-
crometer sections were prepared and used for hematoxylin and eosin
(H&E) staining by the Histology Core Services (University of Maryland).
Stained sections were blinded and analyzed by Lindsay Goicochea at the
University ofMarylandMedical Center Department of Pathology. Images
of histological sections were modified across all sections using Adobe
Photoshop CS5 for only minimal modification of images.
Histology scoring. Slides were prepared as 5-m sections and stained
with hematoxylin and eosin. A pathologist (L.G.) was blinded to mouse
genetic background, as well as infection status. Fields were examined by
light microscopy and analyzed by Lindsay Goicochea (University of
Maryland at Baltimore). The degrees of interstitial, peribronchiolar, and
perivascular inflammation was scored from 0 to 3 (Table 1 provides a
SARS-CoV and Alternatively Activated Macrophages
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description of the scoring methodology). For each experimental group,
Goicochea blindly scored 3mice, and those scores were tabulated to com-
pare strains, time points, and infections. Other histologic features, such as
the presence of reactive bronchiolar epithelial and pleural changes and the
extent of peribronchovascular neutrophilia, were also noted for each
group in the text. A combined score, based on the described pathological
descriptors (Table 1), was generated for eachmouse, and then, 3 mice per
group were averaged and the standard deviation for the scoring was com-
puted. These scores are presented in the histological scoring figures.
Bone marrow chimeras. Bone marrow (BM) chimeras of C57/B6
wild-type (WT) and C57/B6 STAT1/mice were created using standard
chimera techniques.We utilized the congenitally marked CD45.2 C57/B6
WTmice and CD45.1-marked C57/B6 STAT1/mice to be able to track
the bone marrow reconstitution. We harvested bone marrow from the
hind leg bones of both STAT1/ CD45.1 mice and WT CD45.2 mice.
This was done by removing and cleaning the leg bones and then flushing
the bones with Dulbecco’s modified Eagle’s medium (DMEM) to remove
the bone marrow. We then washed the bone marrow cells and resus-
pended them in 10% bovine serum albumin (BSA) in PBS. Both
STAT1/CD45.1 andWTCD45.2 mice were then irradiated with 1,080
rads to achieve complete bone marrow ablation. Immediately following
the irradiation, we injected 4  106 STAT1/ BM cells per mouse into
CD45.2 WT mice, and 4  106 WT BM cells per mouse into CD45.1
STAT1/ mice, via intravenous injection into the tail vein. The mice
were then given enrofloxacin (Baytril) in their drinking water to ward off
infection and allowed to recover and reconstitute for 6 weeks. After 6
weeks, the mice were screened by fluorescence-activated cell sorter
(FACS) on the CD45marker (Santa Cruz Biotechnology, Santa Cruz, CA)
to check for successful reconstitution. Mice that were successfully recon-
stituted (95% reconstitution) weremoved to an animal biosafety level 3
(ABSL3) facility and allowed to rest for 48 h prior to infection.
We then intranasally infected the mice with 1 105 PFU SARS-CoV
rMA15 or mock infected them with a PBS control and monitored the
disease course to identify differences in pathogenesis. We infected and
treated age-matched, unaltered wild-type and STAT1/mice that were
treated similarly with antibiotics prior to their infection as control groups.
We monitored the weight of the mice daily and sacrificed them at day 9
postinfection for analysis. We harvested the lung tissue for pathology,
immunohistochemistry, RNA, protein, and viral-titer assays.
In vivomouse infections. All infections were performed in an animal
biosafety level 3 facility at the University of Maryland, Baltimore, MD,
using appropriate practices, including a HEPA-filtered bCON caging
system, HEPA-filtered powered air-purifying respirators (PAPRs), and
Tyvek suiting. All animals were grown to 10 weeks of age prior to use in
experiments. The animals were anesthetized using a mixture of xylazine
(0.38 mg/mouse) and ketamine (1.3 mg/mouse) in a 50-l total volume
by intraperitoneal injection. The mice were inoculated intranasally with
50 l of either PBS or 1 105 PFU of rMA15 SARS-CoV, after which all
animals were monitored daily for weight loss. Mice were euthanized at
days 2, 5, or 9 postinfection, and lung tissue was harvested for further
analysis. All animals were housed and used in accordance with the Uni-
versity of Maryland, Baltimore, Institutional Animal Care and Use Com-
mittee guidelines.
YM1 and Fizz1 immunohistochemistry. Five-micrometer paraffin
sections of fixed lung tissue were cut by the Histology Core at the Univer-
sity of Maryland, Baltimore. Slides were deparaffinized in xylenes and
rehydrated in an ethanol series. Endogenous peroxidase activity was
quenched by incubating slides in 0.3%hydrogen peroxide inmethanol for
30 min at room temperature (RT). Antigen retrieval was performed by
incubating slides for 20min in IHC select citrate buffer, pH6.0 (Millipore,
Billerica,MA). Tissue sections were then preincubated in 10% goat serum
in PBS for 1 h at RT. Rabbit polyclonal Fizz1 antibody (Abcam, Cam-
bridge, MA) was used at a concentration of 1:100 diluted in 10% goat
serum in PBS. Rabbit polyclonal YM1 antibody (StemCell Technologies,
Vancouver, BC, Canada) was used at a concentration of 1:200 diluted in
10% goat serum in PBS. Sections were incubated in primary antibody for
30min at RT. The slides were washed before incubation with biotinylated
secondary antibody from the ABC Elite Rabbit kit (Vector Laboratories,
Burlingame, CA) for 30 min at RT. The slides were washed again prior to
addition of ABC reagent (Vector Laboratories, Burlingame, CA) for 30
min at RT. After 3 changes of PBS, the slides were developed using DAB
(3,3-diaminobenzidine) for 2 min per slide. Development was stopped
using a 5-min incubation in distilled water (dH2O). A 10-min incubation
in 0.5%methyl green in 0.1 M sodium acetate solution, pH 4.2, was used
for counterstaining. The counterstain was cleared using 2 changes of PBS,
followedby 2 changes ofN-butanol for 2min each. Slideswere dehydrated
using 2 5-min incubations in xylenes before being mounted.
STAT1 immunohistochemistry. Slides with 5-m sections of mouse
lung were obtained from the Histology Core at the University of Mary-
land, Baltimore. The slides were deparaffinized using two changes of xy-
lenes for 5 min each change. An ethanol series was then used to rehydrate
the sections. The slides were then incubated inMOMmouse IgG blocking
reagent from a MOM kit purchased from Vector Laboratories (Burlin-
game, CA) for 1 h at RT. The slides were washed in PBS and then incu-
bated with MOM protein diluent for 5 min at RT. Anti-STAT1 primary
antibody (BD Transduction Laboratories, San Jose, CA) was diluted at
1:100 in MOM protein diluent. The slides were incubated in primary
antibody for 30 min at room temperature. The slides were washed in PBS
before being incubated in MOM biotinylated anti-mouse IgG antibody
provided in the MOM kit for 10 min at RT and washed in 2 changes of
PBS. The biotin signal was amplified using a TSA Plus Biotin kit (Perkin
Elmer, Waltham, MA). The slides were incubated in working-strength
biotin amplification solution made at 1:25 for 5 min at RT and then
washed in 2 changes of PBS. AnABC-Alkaline Phosphatase (AP) kit (Vec-
tor Laboratories, Burlingame CA) was then used. The slides were incu-
bated in ABC-AP for 30 min at RT and then developed using an alkaline
phosphatase kit (Vector Laboratories, Burlingame, CA) by incubating the
slides for 60 min in AP. The slides were then counterstained using methyl
TABLE 1 Histological scoring criteria
Inflammation
Criteria for score of:
0 1 2 3
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green solution before being decolorized, dehydrated in xylenes, and
mounted.
IsolationofDNA from intraperitonealmacrophages andperipheral
blood. Peritoneal macrophages were obtained by injectingmice with 3ml
of sterile 3% thioglycolate broth (Remel, Lenexa, KS) intraperitoneally.
Three days after injection, cells were harvested by lavage of the intraperi-
toneal cavity. The cells were washed in DMEM and pelleted for further
analysis by reverse transcription-PCR. Peripheral blood was collected by
terminal cardiac puncture. DNA was isolated using a DNA/RNA Allprep
kit fromQiagen Laboratories (Valencia, CA). The DNAwas then used for
PCR and analyzed on a 1% agarose gel. The template was amplified by
reverse transcription-PCRusing forward (5=-GCATGACATGATCAGCA
TTGC-3=) and reverse (5=-ACTGACGTCAACCAAGCCTG-3=) primers.
RESULTS
rMA15 infection is cleared from both C57BL/6 and STAT1/
mice. To evaluate the role of STAT1 in SARS-CoV infection in
mice, 10-week-old WT C57BL/6 and C57BL/6 STAT1/ mice
were infected with 1  105 PFU of rMA15. rMA15 is a mouse-
adapted SARS-CoV containing 6 amino acid mutations from the
WT Urbani strain of SARS-CoV that produces lethal disease in
BALB/c mice but does not kill C57BL/6 mice (57). The mice were
weighed daily over a 9-day course of infection (Fig. 1A), during
which lung tissue was harvested at days 2, 5, and 9 for further
characterization. WT C57BL/6 mice lost roughly 15% of their
body weight during the first 4 days postinfection (p.i.) and then
FIG 1 C57BL/6 STAT1/mice are highly susceptible to rMA15. (A) Weight loss in WT and STAT1/mice infected with either rMA15 or PBS control (n
15 for each strain). The error bars indicate standard deviations. (B) rMA15 lung titers in WT and STAT1/ mice (n  5 for each time point). The asterisk
indicates a P value of 0.5, and the dashed line indicates the level of detection. (C) H&E staining of WT and STAT1/ mice infected with rMA15 or mock
infected with PBS at 9 days p.i. (D)Histological scoring of lung sections ofWT and STAT1/mice infected with rMA15 ormock infected with PBS at 9 days p.i.
SARS-CoV and Alternatively Activated Macrophages
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achieved complete recovery of their starting weight by 9 days p.i.
In contrast, STAT1/mice continued to lose weight throughout
the course of infection, losing more than 20% of their starting
weight by 9 days p.i.
Viral titers were analyzed using a plaque assay to compareWT
to STAT1/mouse infections (Fig. 1B).WTmice displayed peak
viral titers at 2 days p.i., with titers of 4.75  107 PFU/g, after
which they decreased by 5 days p.i. to 1.4 104 PFU/g. Viral titers
were below detectable levels by 9 days p.i. STAT1/ mice dis-
played a similar trend, with peak titers of 8.75  107 PFU/g at 2
days p.i. STAT1/mice showed a 2-log-unit increase in titer at 5
days p.i. compared toWTmice but still cleared virus by 9 days p.i.
to below detectable levels (Fig. 1B). Interestingly, despite the dif-
ferences in weight loss, we found thatWT and STAT1/mice on
the C57BL/6 background were able to clear rMA15 virus from
their lungs during infection, although STAT1/mice had higher
virus titers at 5 days p.i.
Inductionofprefibrotic lesions inSTAT1/mice after virus
clearance.Histological analysis was performed on lungs harvested
at 2, 5, and 9 days p.i. in C57BL/6 WT and STAT1/ mice (Fig.
1C andD). As previously reported,WTmice infected with rMA15
show bronchiolar sloughing at 2 days p.i., with significant cell
debris in the bronchioles. A peribronchiolar and periarteriolar
mixed inflammatory infiltrate consisting of eosinophils and neu-
trophils was observed. By 5 days p.i., airways were generally clear
of cell debris and ciliated epithelial cells were present in the bron-
chioles. Inflammation was still present in the WT lungs, present-
ing with mainly eosinophils and macrophages in focal regions,
primarily surrounding small airways. By 9 days p.i., we observed
few small focal aggregates predominantly comprised of lympho-
cytes cuffing around vessels and larger airways; however, in gen-
eral, inflammatory infiltrates were minimal, and the lungs had
returned to their preinfection state.
In C57BL/6 STAT1/mice we found a more severe lung pa-
thology that persisted throughout the course of infection. At 2
days p.i., STAT1/ mice showed lung pathology similar to that
seen in WT mice. Lungs showed evidence of bronchiolar slough-
ing, withmixed inflammatory infiltrates throughout the lung, but
most notably displayed cuffing around large airways and blood
vessels. At 5 days p.i., STAT1/ mice did not have the same
recovery as WTmice, and we found a continued increase in levels
of mixed inflammatory infiltrates comprised of neutrophils and
mononuclear cells, macrophages, and lymphocytes. These infil-
trates continued to cluster around large airways and vessels and
began to fill the alveolar space. By 9 days p.i., there was continued
progression in the severity of lung pathology and there was more
pronounced neutrophilia and increased macrophage numbers
found in the lung interstitium. Lung epithelial cells exhibited
squamous metaplasia, which is a characteristic reactive response
to damage commonly seen in incidents of ALI, especially in orga-
nizing DAD. Interestingly, there was also proliferation of intersti-
tial fibroblasts in both the subpleural and central regions of the
lung. This resembled a prefibrotic-like state sometimes seen fol-
lowing extensive lung damage. H&E-stained slides were blinded
and scored by pathologist Lindsay Goicochea (UMB). The slides
were scored for perivascular, peribronchiolar, and interstitial in-
flammation. The scores were tallied as described in Materials and
Methods and are graphed in Fig. 1D.While pulmonary inflamma-
tion was still found in WT mice at 9 days p.i., we observed that at
9 days p.i. STAT1/mice had statistically significant inflamma-
tion throughout the lung tissue. Collectively, this lung pathology
suggests an inappropriate immune response continuing even after
virus had been cleared to below detectable levels.
Alternatively activated macrophages are induced during
rMA15 infection of STAT1/mice.We observed an expansion
of total macrophages during infection in our histological sections
of STAT1/mice after rMA15 infection. Since we had previously
reported the induction of AA macrophage phenotypes in
STAT1/ mice (79), immunohistochemistry was performed to
look for the presence of proteins commonly associated with AA
macrophages. YM1 and FIZZ1 are both expressed from AA mac-
rophages in the lung during diseases such as allergic airway in-
flammation models and respiratory syncytial virus (RSV) infec-
tion and used as the standard marker of AA macrophage
induction in mice (54, 55). To identify whether AA macrophages
were present in WT and STAT1/ mice, lung sections were
stained with antibodies for YM1 and FIZZ1 to analyze their ex-
pression during rMA15 infection (Fig. 2). Wild-type and
STAT1/ mice were found to express FIZZ1 specifically along
the lung epithelia in PBS-inoculated controls; however, at 9 days
after infection, FIZZ1 protein is highly enriched both in the lung
parenchyma and inmacrophages of STAT1/mice (Fig. 2). This
is in contrast to what is observed in WT mice. In WT mice, we
foundFIZZ1 expression solely associatedwith the lung epithelium
even at 9 days p.i. (Fig. 2). Minimal induction of FIZZ1 was iden-
tified at days 2 and 5 postinfection ofWT or STAT1/mice (Fig.
2). YM1 expression in PBS-inoculated control mice was associ-
ated with alveolar macrophages with little to no expression in the
ciliated lung epithelium of the large airways in both wild-type and
STAT1/mice (Fig. 2). However, at 9 days p.i., STAT1/mice
showed evidence of YM1 still associated with alveolar macro-
phages, but now they displayed diffuse staining in the lung paren-
chyma in addition to increased staining in the ciliated lung epi-
thelial cells. Minimal induction of YM1 was identified at days 2
and 5 postinfection of WT or STAT1/ mice. This increase in
both YM1 and FIZZ1 levels in the lung suggests an increase in AA
macrophages in the SARS-CoV-infected STAT1/mice.
The induction of FIZZ1 from cell types other than macro-
phages has been reported in systems of allergic airway inflamma-
tion (8). To confirm the presence ofmacrophages at sites of FIZZ1
and YM1 expression in these mice, we stained with a panmac-
rophagemarker, F4/80, using immunohistochemistry (Fig. 3).We
detected F4/80-positive cells at the same sites that stained for
FIZZ1 and YM1, which strongly supports the finding that the
positive cells are truly AA macrophages.
Induction of TH2 cytokines, IL-4 and IL-13, during rMA15
infection.Alternatively activatedmacrophages differentiate in re-
sponse to the TH2 cytokines IL-4 and IL-13.Wehypothesized that
we would be able to detect an increase in IL-4 and IL-13 concom-
itant with the induction of AA macrophages in response to infec-
tion in STAT1/ mice. RNA from lungs of WT and STAT1/
micemock infected with PBS or infected with rMA15 was isolated
and used for real-time PCR analysis of IL-4 and IL-13 (Fig. 4).We
found that in WT mice, there was little detectable IL-4 or IL-13
message in either PBS-mock-infected or rMA15-infected mice.
However, in STAT1/ mice infected with rMA15, we found a
significant increase in IL-4 and IL-13 mRNAs at 5 days p.i., which
was then reduced by 9 days p.i. The increase at 5 days p.i. correlates
with the induction of AA macrophages seen beginning at 5 days
p.i. and increasing through 9 days p.i. (Fig. 2). Once the induction
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FIG 2 Alternatively activated macrophages are induced during rMA15 infection of STAT1/ mice. Immunohistochemistry was performed in lung sections
from WT and STAT1/mice after either PBS inoculation or rMA15 infection at 2, 5, and 9 days p.i. The sections were stained for the alternatively activated
macrophage markers FIZZ1 and YM1. The images showing 10 resolution focused on airway labeling and those at 40 resolution focused on the pulmonary
interstitium to highlight the extent of signal.
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ofAAmacrophages occurs, IL-4 and IL-13 are no longer needed to
continue the TH2 polarization in STAT1/mice.
STAT1 is necessary in the hematopoietic lineage to protect
fromrMA15pathogenesis.Ourdata suggest that STAT1/mice
have a dysregulated response to SARS-CoV infection, leading to a
more severe disease phenotype and delayed clearance of virus.
Immunohistochemical results suggest that part of this response is
related to a change in macrophage phenotype and polarity. We
next sought to determine if cells from the hematopoietic lineage
were responsible for these changes in outcome following infec-
tion. In order to test this, we developed bone marrow chimeric
mice by lethally irradiating mice and transferring congenitally
marked bone marrow; STAT1/ bone marrow was injected into
wild-type mice, and wild-type bone marrow was injected into
STAT1/mice. After screening using theCD45marker onCD4	
cells to confirm successful reconstitution (Fig. 5A), the mice were
infected with 1 105 PFU of rMA15 and weighed daily for 9 days.
Mouse lungs were harvested at days 2, 5, and 9 postinfection for
analysis. Quantification of virus titers was performed on lung tis-
sue to evaluate the ability of each mouse to clear virus. We ob-
served that all groups had peak viral titers at 2 days p.i., with titers
beginning to diminish by 5 days p.i. By 9 days p.i., virus was below
detectable levels (Fig. 5B). The STAT1/ mice receiving wild-
type bone marrow displayed a minor delay in clearance at 5 days
p.i., while wild-type mice receiving STAT1/ bonemarrow were
indistinguishable from normal wild-type mice.
Lung sections from bone marrow chimera mice were analyzed
for the severity of lung pathology after infection (Fig. 5C). At 9
days p.i., the lung pathology was significantly different between
the two chimera groups. In STAT1/ mice that received wild-
type bone marrow, there was damage to the large airways, partic-
ularly to the ciliated epithelial cells that line the airways. Cell de-
bris was also still observed in the bronchiolar airspace. Thesemice
also had mixed inflammatory infiltrates that were found cuffing
these damaged airways and vessels throughout the lung. Interest-
ingly, these inflammatory infiltrates followed a focal pattern as
opposed to the diffuse inflammation seen in the total STAT1/
animals.
In contrast, WT mice that received STAT1/ bone marrow
exhibited less overall damage to the ciliated epithelial cells of the
large airways but displayed enhanced inflammatory infiltrates and
both perivascular and peribronchiolar cuffing. There remained
foci of reactive squamousmetaplasia, but largely, the airways were
healthy and intact.We observed a diffuse pattern of inflammation
throughout the interstitium comprised of neutrophils and mac-
rophages marked by almost complete collapse of the alveolar
space. We also found perivascular neutrophilia, as well as lym-
phoplasmocytic infiltrates, throughout the lung parenchyma. The
inflammation seen in the lungs of these wild-type mice receiving
STAT1/ hematopoietic cells closely resembled that of total







FIG 3 Immunohistochemical staining of lung sections fromWT, STAT1/,
LysM/STAT1, STAT1/6/, and STAT6/mice for the macrophage marker
F4/80 to identify the locations ofmacrophages in lung sections. Brown staining












































FIG4 RNA fromWTand STAT1/mice at 2, 5, and 9 days p.i. was extracted
from mouse lungs, converted to cDNA, and used to analyze the induction of
IL-4 and IL-13 mRNAs. Three mice were used for each time point and strain.
The fold change was calculated by comparison of the total induction for each,
normalized to 18S rRNA levels and divided by the PBS control. The error bars
indicate standard deviations.
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suggests that one or more cell types from STAT1/ mice are
important contributors to the prolonged lung damage after
rMA15 infection.
Deleting STAT1 from macrophages and monocytes pro-
duces disease similar to that in complete STAT1/mice. After
confirming that cells of hematopoietic lineage were predomi-
nantly responsible for the increase in pathology in total STAT1/
mice, we sought to identify potential cell types that could be spe-
cifically responsible for this pathology. Together, the hematopoi-
etic link and the increase in AA macrophage markers led us to
hypothesize that STAT1 contributes to shaping macrophage re-
sponses during SARS-CoV infection and that a change in macro-
phage polarization was leading to severe lung disease. To test this,
we developed 2 mouse strains in which STAT1 is conditionally
knocked out. In one strain, we crossed mice containing a STAT1/
LoxP integrant with a LysM promoter-driven Cre recombinase to
delete STAT1 inmonocytes (mice referred to as LysM/STAT1). In
the second strain, we crossed mice containing the same STAT1/
LoxP integrant with a FoxJ1 promoter-driven Cre recombinase to
delete STAT1 in ciliated epithelial cells (77). While we hypothe-
FIG 5 STAT1 is necessary in the hematopoietic lineage to protect from rMA15 pathogenesis. Bone marrow chimera experiments between WT and STAT1/
mice were performed. (A) FACS plot of CD45.1 and CD45.2 CD4	 cells to confirm reconstitution after irradiation. (B) Lung titers from WT, STAT1/, and
reconstituted mice after infection with rMA15 at 2, 5, and 9 days p.i. (n  5 for each time point). #, not significant compared to WT day 5. The dashed line
indicates the level of detection. (C)H&E staining ofWT, STAT1/, and bonemarrow-reconstitutedmice eithermock infectedwith PBS or infectedwith rMA15
at 9 days p.i. Notice the enhanced inflammation in STAT1/ and STAT1(donor)¡WT(recipient) lungs after infection. (D)Histological scoring of lung sections
in panel C. *, not significant compared to WT on day 9. The error bars indicate standard deviations.
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sized that STAT1 was modulating the macrophage response, we
created the FoxJ1/STAT1 mouse strain to control for the effect of
STAT1 in ciliated epithelial cells, which are the primary target of
SARS-CoV in the lung (77). The FoxJ1/Cre mouse has been ana-
lyzed and displays specific expression in the ciliated cells of the
respiratory epithelium, as well as the choroid plexus, ependyma,
oviduct, and testis (77). SARS-CoV specifically infects the respi-
ratory epithelium, so expression in other tissues does not compli-
cate the analysis. To confirm the deletion of STAT1 in monocytes
and macrophages in LysM/STAT1 mice, we used thioglycolate to
induce intraperitoneal macrophages in WT, STAT1/, and
LysM/STAT1mice to compare deletions (Fig. 6A). We confirmed
deletion of STAT1 using gene-specific primers and found that in
macrophages, a higher-molecular-weight band is found in WT
mice than in LysM/STAT1 mice, demonstrating the deletion, and
no band is found in the STAT1/ mice, as is expected with the
primers used. In blood, where the LysMpromoter is not active, we
donot see a deletion in the LysM/STAT1mice, demonstrating that
LysM/Cre is specific tomonocytes andmacrophages. To verify the
FoxJ1/STAT1 deletion in ciliated epithelial cells, we used IHC
staining for STAT1 to compare WT, STAT1/, and FoxJ1/
STAT1 mouse airways (Fig. 6B). We found high levels of expres-
sion of STAT1 in WT mice and no expression in any lung cells in
STAT1/mice. In FoxJ1/STAT1 mice, we found STAT1 expres-
FIG 6 Pathogenesis of rMA15 in LysM/STAT1 and FoxJ1/STAT1 mice. (A) PCR confirmation for LysM/STAT1 mice showing STAT1 deletion only in
monocytes and macrophages and not in blood of transgenic mice used for the experiments. The arrow indicates the WT STAT1 band, and the arrowhead
indicates a deleted STAT1 band. (B) Immunohistochemical labeling of STAT1 in WT, STAT1/, and FoxJ1/STAT1 mice to confirm deletion of STAT1 in
ciliated epithelial cells. Lung sections were stained with anti-STAT1 antibody. The bright red color is positive staining with antibody. Note in the FoxJ1/STAT1
image that alveolar cells and Clara cells are positive but ciliated epithelial cells are negative for staining. (C)Weight loss curve of mice infected with rMA15 (n
5 for each time point). The error bars indicate standard deviations. (D) Histological scoring of H&E-stained lung sections in panel E. (E) H&E staining of WT,
STAT1/, and LysM/STAT1 mouse lungs after infection with rMA15 or mock infection with PBS control at 9 days p.i.
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sion in the Clara cells of the airways and throughout the alveoli;
however, STAT1 expression was lacking in ciliated airway epithe-
lial cells, confirming correct deletion of STAT1 in FoxJ1/Cre-ex-
pressing cells.
The 10-week-old WT, STAT1/, LysM/STAT1, and FoxJ/
STAT1 mice were inoculated with 1  105 PFU of rMA15 and
were weighed daily for 9 days (Fig. 6C).WTmice displayed a 10%
startingweight loss by day 3 postinfection, with themice regaining
100% of their starting weight by 9 days p.i. STAT1/ mice lost
10% of their starting weight during the first 3 days and then, as
before, lost more than 20% of their starting weight through 9 days
p.i. Additionally, FoxJ/STAT1mice had weight loss very similar to
that of WT mice. We observed 10% weight loss by 3 days p.i. and
then complete recovery by 9 days. Interestingly, LysM/STATmice
displayed early weight loss that closely followed that of the total
STAT1/mice and exceeded STAT1/mouse weight loss by 4
days p.i.; however, they also proceeded to recover their body
weight by 9 days postinfection, albeit more slowly thanWTmice.
H&E-stained lung sections were analyzed to determine the de-
gree of lung damage and inflammation in the conditional knock-
out mice following infection with rMA15. As before, at 9 days p.i.,
we found minimal residual inflammation in WT mice, while
STAT1/ mice displayed overactive and uncontrolled inflam-
mation cuffing the vasculature, bronchi, and throughout the in-
terstitium (Fig. 6E).We observed that LysM/STAT1mice had per-
sistent inflammation throughout the lung, and specifically, we
found cuffing of the large airways, as well as the vessels. The LysM/
STAT1 lungs contained inflammatory infiltrates comprised of
neutrophils, as well as macrophages, with lymphoid aggregates
throughout the interstitial space. Along with these aggregates,
there was also evidence of foci of fibroblast proliferation, which is
consistent with a prefibrotic-like state seen in total STAT1/
mice infected with rMA15 (15). In comparison, FoxJ1/STAT1
mice do not display this increased inflammatory response upon
infection with rMA15. We found minimal residual inflammation
throughout the lungs of infected mice at 9 days p.i. These mice
looked comparable to WT mice at the same time point, with re-
paired ciliated epithelial cells and no observed cuffing of vascula-
ture or bronchi. Histological scoring demonstrated a reduced
score in FoxJ/STAT1mice similar to that ofWTmice at 9 days p.i.,
while LysM/STAT1 mice were found to have a higher score, sim-
ilar to that of STAT1/mice at 9 days p.i. (Fig. 6D).We conclude
that the LysM/STAT1 lung pathology is very similar to the full
STAT1/ lung pathology seen during infection and hypothesize
that dysregulation of the monocyte and macrophage cell popula-
tion by deletion of STAT1 specifically in these cells leads to en-
hanced lung injury and disease after rMA15 infection.
Alternatively activated macrophages are induced in LysM/
STAT1 mice after infection with rMA15 similarly to induction
in total STAT1/ mice. After infection of rMA15 in total
STAT1/ mice, we found induction of AA macrophages in the
lungs. Given the above finding that LysM/STAT1 mice have lung
pathology similar to that of STAT1/ mice but that FoxJ1/
STAT1 mice have pathology similar to WT mice, we sought to
identify whether the induction of AA macrophages correlated
with lung disease. In order to examine the activation profile of
macrophages following infection, immunohistochemistry was
performed on lung sections from mice harvested at 9 days p.i.
Mouse lungs were fixed in 4% PFA and embedded in paraffin for
sectioning and staining with antibodies for YM1 and FIZZ1,
markers for AA macrophage presence (Fig. 7). After staining for
YM1 and FIZZ1, we observed that WT mice showed very little
detectable YM1 or FIZZ1 in both uninfected and infectedmice. In
STAT1/mice, we found high levels of YM1 expression by 9 days
p.i. associated with macrophages throughout the lungs (Fig. 2).
FIZZ1 is found highly induced in the airway epithelial cells of
STAT1/ mice after infection, as well as collecting in pools of
proteinaceous fluid found in foci throughout the interstitium
(Fig. 2). In LysM/STAT1mice, YM1 levels were found to be low in
PBS inoculation control mice, but at 9 days p.i., the levels were
increased and protein could be detected throughout the lung tis-
sue, similar to what is seen in STAT1/ mice (Fig. 7). FIZZ1
levels were also low in uninfected LysM/STAT1 mice; however,
similar to YM1, these levels were elevated at 9 days p.i. (Fig. 7).We
observed FIZZ1 staining diffusely throughout the lung paren-
chyma at this time point, and FIZZ1 was again found collecting in
fluid-filled foci in the interstitium. Conversely, FoxJ1/STAT1
mice displayed very little induced YM1 or FIZZ1 at 9 days p.i. with
rMA15 (Fig. 7). Minor induction of YM1 was found after infec-
tion; however, it was found at background levels, as seen in WT
mice. Collectively, these data suggest that STAT1 plays a role in
macrophage polarization during infection with SARS-CoV and
that when macrophages lack STAT1, they are increasingly of an
alternatively activated phenotype and are induced during rMA15
infection.
Inhibition of AAmacrophages in STAT1/mice eliminates
severe lung disease. Our data suggest that AA macrophages are
associated with enhanced lung disease after SARS-CoV infection.
We hypothesized that thesemacrophages could be contributing to
the exacerbated lung damage, since they have been previously
shown to be involved in altered lung repair pathways in fibrosis
(48, 69) and asthma (3, 4, 30, 43, 68). Development of AAmacro-
phages is completely dependent on the STAT6 transcription factor
(7, 34, 41). Inmice lacking STAT6, no AAmacrophages are found
after treatment with several AA macrophage inducers (7, 34, 41).
We created STAT1/  STAT6/ double-knockout mice
(called STAT1/6/) that contain the STAT1 deletion but lack the
ability to produce AA macrophages and thus YM1 and FIZZ1.
As before, we infected these mice and STAT6/mice, to con-
trol for a phenotype with the loss of STAT6, with rMA15. WT,
STAT1/, STAT6/, and STAT1/6/mice were infected with
1  105 PFU of rMA15 and weighed daily for 9 days (Fig. 8A).
Weight loss forWT and STAT1/mice was consistent with what
was observed in previous experiments. WTmice lost 10% of their
body weight during the first 3 days postinfection and then re-
gained 100% of their body weight by 9 days p.i. Also, STAT1/
mice lost more than 20% of their body weight by 9 days p.i.
STAT6/mice displayed weight loss similar to that of WTmice,
with early weight loss by day 3, but then regained weight through
9 days p.i. Interestingly, STAT1/6/ mice also displayed 10%
weight loss by day 3, but unlike STAT1/ mice, the double-
knockout mice regained weight and had returned to their starting
weight by 9 days p.i.
Mouse lungs were harvested and analyzed for histological le-
sions by H&E staining (Fig. 8B). WT and STAT1/ mice dis-
played similar lung pathology, as found previously, with minimal
residual inflammation in WT mice at 9 days p.i., but STAT1/
mice displayed severe inflammatory infiltrates around blood ves-
sels and airways and throughout the interstitium. Consistent with
the weight loss data, STAT1/6/mice displayedminimal inflam-
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mation and lung damage after rMA15 infection, similar to WT
mice (Fig. 8B). Histological scoring of lung sections demonstrated
reduced lung damage and inflammation in both STAT6/ and
STAt1/6/ mice, corroborating the weight loss data (Fig. 8C).
Together, these data suggest that elimination of AA macrophages
in a STAT1/ background is able to abrogate induced lung dis-
ease and inflammation after rMA15 infection.
To confirm that AA macrophage development was inhibited
during infection, we again analyzed YM1 and FIZZ1 induction by
IHC as markers of AA macrophage levels in lung tissue (Fig. 9).
Lung sections fromWT, STAT1/, STAT6/, and STAT1/6/
mice inoculated with PBS or rMA15 were analyzed. WT and
STAT6/mice displayedminimal YM1 and FIZZ1 expression in
rMA15-infectedmice, while STAT1/mice displayed high levels
of both YM1 and FIZZ1, as observed previously. Concomitant
with weight loss and H&E staining, we found low levels of FIZZ1
and YM1 staining in STAT1/6/ mice with either PBS inocula-
tion or rMA15 infection. The level of staining was similar to that
observed in WT mice after infection. This demonstrates that the
STAT1/6/ mice have decreased numbers of AA macrophages
and that this reduction correlates with decreased lung pathology.
Together, these data demonstrate that in a STAT1/ mouse
model where AA macrophages are eliminated there is reduced
lung pathology and disease after rMA15 infection. We interpret
this to mean that AA macrophages contribute to the severe lung
disease seen in STAT1/ mice and that even in the presence of
total STAT1 deletion, the removal of AA macrophages inhibits
disease progression, prefibrotic lesions, and the enhanced inflam-
matory infiltrate. We hypothesize that the inhibition of the AA
macrophage induction pathway could be a therapeutic target for
SARS-CoV infection, as well as that of other highly acute respira-
tory viruses that may induce similar pathways during infection.
DISCUSSION
The interaction between host and pathogen controls the outcome
of an infection. From the virus side, many viral proteins from a
wide range of viruses directly affect host cell function during in-
fection. From the host side, the response to infection can exacer-
bate disease and lead to increased damage, causing more destruc-
tion than the viral infection alone. In this series of experiments, we
have shown that the host response to SARS-CoV infection is able
to exacerbate disease and that the host protein STAT1 is important
for controlling that response.
The repair of lung tissue after infection or mechanical trauma
normally occurs in a rapid, but controlled series of events: inflam-
mation, growth factor secretion, basement membrane repair, and
finally resolution of the injured tissue (58).Under normal circum-
stances, this process proceeds without any problems; however,
when the infectious burden overwhelms the host or there is con-
tinuous damage, the wound-healing response can become dys-
FIG 7 Alternatively activatedmacrophages are induced during rMA15 infection of LysM/STAT1/mice but not FoxJ/STAT1/mice. IHCwas performed in
lung sections from LysM/STAT1 and FoxJ/STAT1 mice after either PBS inoculation or rMA15 infection at 9 days p.i. The sections were stained for the
alternatively activated macrophage markers FIZZ1 and YM1. The images showing 10 resolution focused on airway labeling, and those at 40 resolution
focused on the pulmonary interstitium to highlight the extent of signal.
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regulated, resulting in scarring and fibrosis (39, 61). When scar-
ring develops into ARDS and pulmonary fibrosis, lung function is
reduced, which can ultimately lead to death. Both ARDS and pul-
monary fibrosis are traditionally treated with corticosteroids,
which act to dampen the immune response; however, this course
of treatment has not been shown to be particularly effective (38,
53). In cases where the etiology is an infectious agent, such a treat-
ment can actually be harmful to the patient, as it delays the clear-
ance of the pathogen (6, 17, 76).
After injury occurs, there is a cascade of events that progress
from initiation of the wound-healing response to recruiting in-
flammatory cells and fibroblasts to resolution of the wound. Al-
FIG 8 Pathogenesis of rMA15 in STAT1/6/mice. (A)Weight loss curves ofWT and STAT1/6/mice infected with rMA15 (n 5 for each time point). The
error bars indicate standard deviations. (B) H&E staining of WT, STAT1/, STAT6/, and STAT1/6/mice either mock infected with PBS or infected with
rMA15. (C) Histological scoring of H&E- stained mouse lungs for WT, STAT1/, STAT6/, and STAT1/6/mice at 9 days p.i.
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FIG 9 Immunohistochemical staining of lung sections fromWT, STAT1/, STAT6/, and STAT1/6/mice for AAmacrophage markers YM1 and FIZZ1.
Brown staining is positive staining with antibody. All sections are from either PBS-inoculated or rMA15-inoculated mice at 9 days p.i.
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teration in any of these cascades can drive the host to induce de-
velopment of fibrosis in the tissue that is in need of repair. Several
factors have been shown to be involved in pushing a profibrotic
spectrum in animal models; however, these targets have yet to be
therapeutically validated in human studies (20, 52, 74). A novel
pathway in this process is the STAT1/EGFR signaling axis. Muta-
tions in STAT1 have been found in many cancers throughout the
body, especially the lung (21, 71). STAT1 has been shown to acti-
vate cell cycle arrest and apoptosis and has demonstrated the
properties consistent with a tumor suppressor. Additionally,
STAT1/ mouse embryonic fibroblasts (MEFs) are highly sus-
ceptible to uncontrolled cell growth compared toWTMEFs (70),
and STAT1/mice display increased sensitivity to radiation (12,
22) and bleomycin-induced fibrosis (70).
In viral models of chronic airway infection using Sendai virus
as the inducer, STAT1 expression in airway epithelial cells has
been shown to be key to protecting against severe lung disease
(63). In this model, STAT1/mice are highly susceptible to Sen-
dai virus, and using bonemarrow chimeras ofWT and STAT1/
mice, it was found that in STAT1/mice reconstituted withWT
bonemarrow, the enhanced susceptibility remained, but not with
the converse reconstitution. This result is the opposite of what we
found for SARS-CoV infection in the above-mentioned bone
marrow chimera experiment and suggests that the intimate and
virus-specific interactions between the virus and host can modify
the inflammatory and disease states. Using the same model of
Sendai virus-induced chronic airway infection, Kim et al. found
that even after viral clearance, induction of natural killer T (NKT)
cells activates macrophages in the lung (23). These macrophages
andNKT cells secrete IL-13, which polarizes macrophages into an
alternatively activated macrophage subtype. This activation pro-
duces a positive-feedback loop to amplify IL-13 production and
alternative activation of macrophages (23). Importantly, the au-
thors found that it is the persistent activation of the AA macro-
phage pathway that is critical to the continued lung damage and
inflammation.
In our previous study, we showed the result of infection by
rMA15 in 129/Sv STAT1/mice, which display a phenotype dif-
ferent in important ways from that of C57BL/6 STAT1/ mice
(15).We found that 129/Sv wild-typemice infected with amouse-
adapted SARS-CoV (rMA15) lose around 15% of their starting
weight but recover that weight over a 9-day course of infection. In
129/Sv STAT1/mice infected with the same virus, we observed
a similar initial weight loss; however, the mice do not recover and
lose20% of their starting weight by 9 days p.i. and/or succumb
to the infection. The STAT1/ mice develop acute lung injury
with the development of pre-pulmonary-fibrosis-like lesions con-
sisting of alternatively activated macrophages, eosinophils, neu-
trophils, and fibroblasts. In this study, we wanted to identify what
the key mediator of the lung lesions was and what cell type neces-
sitated STAT1 for protection.
In this work, we utilized mice on the C57BL/6 genetic back-
ground and a STAT1/mouse, also on this background (10).We
switched to C57BL/6 background mice in this work for several
reasons. First, we found that, unlike 129/Sv STAT1/ mice,
C57BL/6 STAT1/ mice do not die during the infection, allow-
ing us a longer period of pathogenesis for analysis. Second, there
are no congenic markers like CD45.1 and CD45.2 in the 129/Sv
background to allow the bonemarrow chimera experiments to be
performed. Third, the FoxJ1/Cre and LysM/Cre mice are only on
the C57BL/6 background to allow us to perform the Cre/LoxP
experiments. Finally, and most importantly, the C57BL/6
STAT1/ mice are able to clear rMA15 during the course of
infection while still producing the same lung pathology as 129/Sv
STAT1/mice. This provides us a more realistic model without
the issue of continued viral replication potentially altering the
results.
Using the C57BL/6 mouse model, we found that mice infected
with rMA15 presented with
10% weight loss through 4 days of
infection and that the mice recovered to their starting weight by 9
days p.i. Importantly, in WT C57BL/6 mice, the rMA15 virus is
cleared by 9 days p.i., and it is also cleared in the STAT1/mice,
unlikewhat is seen in 129/Sv STAT1/mice (15). Evenwith virus
clearance, the STAT1/ mice still developed pre-pulmonary-
fibrosis-like lesions in the lungs by 9 days p.i. This suggests that, as
we hypothesized, the STAT1 protein has a role in the development
of lung pathology in addition to its role in the innate immune
response to infection.
Based on previous data, we predicted that STAT1was playing a
role either in the lung ciliated epithelial cells, which are the only
cells in the lung that are infected by SARS-CoV (64), or in macro-
phages, since we found an altered macrophage response in total
STAT1/ mice infected with rMA15 (79). Using this C57BL/6
model, we produced mice that lacked STAT1 in only specific cell
types, either FoxJ1/STAT1 mice (77) or LysM/STAT1 mice (5).
FoxJ1/STAT1 mice have STAT1 deleted in the ciliated airway ep-
ithelial cells, and LysM/STAT1 mice have STAT1 deleted in
monocytes and macrophages. FoxJ1/STAT1 mice infected with
rMA15 displayed lung pathology, weight loss, and virus growth
kinetics similar to those ofWT C57BL/6 mice. LysM/STAT1mice
displayed severe lung pathology and a cytokine response similar to
that of total STAT1/mice. Interestingly, the weight loss was not
significantly different from that of WT mice, suggesting that
weight loss and lung pathology may be separate responses during
infection. While the lung pathologies and the AA macrophage
induction in STAT1/ and LysM/STAT1 mice are very similar,
the weight loss is not, with LysM/STAT1-infected mice regaining
their weight through the experiments. We hypothesize that this
difference may be due to the role of STAT1 in cytokine induction
from host cells and that this induction involves unidentified host
response factors affecting morbidity and subclinical symptoms of
mice. We are currently using transcriptomics and mathematical
modeling to identify pathways contributing to weight loss and
pathogenesis in these mice.
The LysM/STAT1 mice developed lung pathology very similar
to that of the total STAT1/mice. When assayed for the induc-
tion of alternatively activated macrophages, which we suspect are
critical for the development of these lesions, we found significant
upregulation of this macrophage population compared to WT
mice and to levels very similar to those in total STAT1/ mice.
Recently, it has been shown that macrophages isolated from pa-
tients with idiopathic pulmonary fibrosis (IPF) have an increased
number of alternatively activated macrophages, as shown by the
human AA macrophage markers of increased CD163 and de-
creased inducible nitric oxide synthase (iNOS) expression (60). In
order to evaluate the role of the AAmacrophagesmore closely, we
crossed STAT6/ mice, which are known to have a blocked AA
macrophage phenotype (59), with our STAT1/ mice. These
STAT1/6/ mice developed disease in a manner that replicated
that seen in wild-type mice and also lacked induction of AA mac-
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rophage-associated proteins YM1 and Fizz1. This further sup-
ports our hypothesis that AAmacrophage induction in STAT1/
mice is responsible for the enhanced disease phenotype.
Together, our findings demonstrate that control of the AA
macrophage response is critical during the response to acute lung
injury, potentially from a variety of etiologies, and that STAT1 is
an important mediator of the development of AA macrophages
during infection. We are actively investigating the role of this
pathway in other models of chronic inflammation in the lung to
identify the role of AA macrophages, STAT1, and the inflamma-
tory response in the induction and maintenance of lung disease.
We hypothesize that if we can modulate the host response during
infection to skew the classical versus alternatively activated mac-
rophage induction pathways, we may be able to alter the disease
outcome in cases of ALI and limit the development of fibrotic-like
disease.
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